| Bayer Presents Latest Data from Oncology Portfolio at 2024 ASCO Annual Meeting
|
| Press Release
|
| Bayer will present new data at the ASCO Annual Meeting, featuring NUBEQA® (darolutamide) and XOFIGO® (radium Ra 223 dichloride) for prostate cancer treatment, including a post hoc analysis from the ARASENS trial and a follow-up analysis from the ARAMIS trial. Additionally, Bayer will share data on BAY 2927088 in HER2-mutant non-small cell lung cancer from the SOHO-01 trial and highlight long-term efficacy and safety data from the VICTORIA study for VITRAKVI® in patients with tropomyosin receptor kinase (TRK) fusion cancer.
|
|
|
|
|
|
|
|
|
|
|
WHAT TO EXPECT FROM THE 2024 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING |
|
|
|
|
|
|
| Advancements in Urothelial Cancer Care: Optimizing Treatment for Your Patient |
|
|
|
|
Optimal Treatment Intensity for Frontline Therapy for Advanced Urothelial Cancer: Which Regimen for Which Patient?
Presented By: Pooja Ghatalia, MD
|
|
|
|
|
Using Molecular Testing to Guide Perioperative Systemic Therapy for Urothelial Cancer
Presented By: Matt D. Galsky, MD, FASCO
|
|
|
|
|
Bladder-Sparing Treatment Strategies for Localized Urothelial Cancer
Presented By: Brent S. Rose, MD
|
|
|
|
|
|
|
| Rapid Oral Abstract Session: Genitourinary Cancer—Kidney and Bladder |
|
|
|
|
Quantitative Circulating Tumor DNA Assessment in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab or Platinum-Based Chemotherapy from the Phase 3 KEYNOTE-361 Trial
Presented By: Thomas Powles, MD, PhD, FCRP
|
|
|
|
|
| State-of-the-Art Diagnostic and Therapeutic Strategies in Renal Cell Carcinoma: Current Advances and Future Frontiers
|
|
|
|
|
Integration of Functional Imaging in Renal Cell Carcinoma
Presented By: Shankar Siva, PhD
Harnessing the Immune System in Renal Cell Carcinoma: Current and Novel Immunotherapy Approaches Presented By: David A. Braun, MD, PhD
Advanced Sequencing and Targeted Therapy Strategies in Renal Cell Carcinoma: How Can We Help More Patients Not at the Expense of Toxicity?
Presented By: Yu-Wei Chen, MD, MS
|
|
|
|
|
|
|
|
|
|
| Oral Abstract Session: Genitourinary Cancer—Prostate, Testicular, and Penile |
|
|
|
|
CYCLONE 2: A Phase 3 Study of Abemaciclib with Abiraterone in Patients with Metastatic Castration-Resistant Prostate Cancer
Presented By: Matthew Raymond Smith, MD, Ph.D.
|
|
|
|
|
Health-Related Quality of Life and Pain in a Phase 3 Study of [177Lu]Lu-PSMA-617 in Taxane-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer (PSMAfore)
Presented By: Karim Fizazi, MD, Ph.D.
|
|
|
|
|
Health-Related Quality of Life Results from PRESTO (AFT-19), a Phase 3 Randomized Trial of Intensification of Androgen Blockade in Patients with High-Risk Biochemically Relapsed Castration Sensitive Prostate Cancer
Presented By: Ronald C. Chen, MD, FASCO, MPH
|
|
|
|
|
|
|
|
|
| Poster Session: Genitourinary Cancer—Kidney and Bladder |
|
|
|
|
4532: Subcutaneous Nivolumab vs Intravenous NIVO in Patients with Previously Treated Advanced or Metastatic ccRCC: Safety and Patient-Reported Outcomes of the Randomized Phase 3 CheckMate 67T Trial
Presented By: Maria Bourlon, MD, MSc
|
|
|
|
|
4562: Enfortumab Vedotin with Pembrolizumab Versus Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma: Analysis of Cisplatin-Eligible Population from EV-302/KEYNOTE-A39
Presented By: Jens Bedke, MD
|
|
|
|
|
4563: Enfortumab Vedotin with Pembrolizumab Versus Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma: Analysis of the Cisplatin-Ineligible Population from EV-302/KEYNOTE-A39
Presented By: Michiel Simon Van Der Heijden, MD, PhD
|
|
|
|
|
4564: Study EV-103: Neoadjuvant Treatment with Enfortumab Vedotin Monotherapy in Cisplatin-Ineligible Patients with MIBC—2-Year Event-Free Survival and Safety Data for Cohort H
Presented By: Peter O'Donnell, MD
|
|
|
|
|
4598: Cost-Effectiveness Analysis of Nadofaragene Firadenovec for the Treatment of High-Risk, Bacillus Calmette-Guerin–unresponsive, Non-Muscle Invasive Bladder Cancer from a US Third-Party Payer Perspective
Presented By: Min Yang, MD, Ph.D.
4601: Final Results of CORE-001: A Phase-2, Single Arm Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in Patients with BCG-Unresponsive, Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
Presented By: David A. Braun, MD, PhD
|
|
|
|
|
|
|
|
|
|
TPS4611: Zanzalintinib (XL092) plus Nivolumab in Non-Clear Cell Renal Cell Carcinoma: The Randomized Phase 3 STELLAR-304 Study
Presented By: Sumanta Kumar Pal, MD, FASCO
|
|
|
|
|
TPS4615: Enfortumab Vedotin plus Pembrolizumab in the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology: A Phase II Study
Presented By: Bassel Nazha, MD, MPH
|
|
|
|
|
TPS4616: Phase 3 Study of Disitamab Vedotin with Pembrolizumab vs Chemotherapy in Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (DV-001)
Presented By: Matt D. Galsky, MD, FASCO
|
|
|
|
|
TPS4622: ENLIGHTED Phase 3 Study: Efficacy and Safety of Padeliporfin Vascular Targeted Photodynamic Therapy for Treatment of LG UTUC
Presented By: Genia Alpert, MD, Ph.D.
|
|
|
|
|
5020: Utility of ctDNA Burden as a Prognostic Biomarker for Efficacy in TALAPRO-2: A Phase 3 Study of Talazoparib + Enzalutamide vs Placebo + ENZA as First-Line Treatment in Patients with mCRPC
Presented By: Arun Azad, PhD, MBBS, FRACP
|
|
|
|
|
5021: Discovery of a Novel Non-Negative Matrix Factorization-Based Homologous Recombination Deficiency Score and Subsequent Exploration in TALAPRO-2, a Phase 3 Study of Talazoparib + Enzalutamide vs PBO + ENZA as First-Line Treatment in Patients with mCRPC
Presented By: Karim Fizazi, MD, Ph.D.
|
|
|
|
|
5022: Association Between Prostate-Specific Antigen (PSA) Level <0.2 ng/mL and Risk of Radiological Progression in Patients (Pts) with Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): Follow-up Analysis of ARAMIS
Presented By: Alicia K. Morgans, MD, MPH, FASCO
|
|
|
|
|
5023: Exploration of Circulating Tumor Cell Conversion and CTC0 as Prognostic Biomarkers for Efficacy in TALAPRO-2: Phase 3 Study of Talazoparib + Enzalutamide vs Placebo + ENZA as First-Line Treatment in Patients with mCRPC
Presented By: Steven Yip, MD, MSc
|
|
|
|
|
5083: Post-Progression Survival of Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Who Received Darolutamide or Placebo: Post Hoc Analysis of ARASENS
Presented By: Marc-Oliver Grimm, MD
|
|
|
|
|
5084: EMBARK post hoc analysis of sexual activity patient-reported outcomes in patients who were sexually active or interested in sex at baseline
Presented By: Stephen J. Freedland, MD
5100: COBRA: Assessment of safety and efficacy of 64Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive therapy
Presented By: Luke Nordquist, MD
TPS5129: CLARIFY: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Patients with High-Risk Prostate Cancer Prior to Radical Prostatectomy (A Phase 3 Diagnostic Study)
Presented By: Michael A. Gorin, MD
|
|
|
|
|
|
|
|
|
|
TPS5122: Darolutamide plus Androgen-Deprivation Therapy in Patients with High-Risk Biochemical Recurrence of Prostate Cancer: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (ARASTEP)
Presented By: Alex Chehrazi-Raffle, MD
|
|
|
|
|
TPS5127: ALADDIN: Evaluation of Darolutamide Addition to Androgen Deprivation Therapy and Radiation Therapy in Newly Diagnosed Prostate Cancer with Pelvic Lymph Nodes Metastases
Presented By: Stephane Oudard, MD, Ph.D.
|
|
|
|
|
|
|
| Oral Abstract Session: Genitourinary Cancer—Kidney and Bladder |
|
|
|
|
Patient-Reported Outcomes from a Randomized, Phase 3 Trial of Enfortumab Vedotin plus Pembrolizumab Versus Platinum-Based Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
Presented By: Shilpa Gupta, MD
|
|
|
|
|
Impact of Exposure on Outcomes with Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer
Presented By: Daniel P. Petrylak, MD
|
|
|
|
|
Biomarker Analyses in Patients with Advanced Renal Cell Carcinoma from the Phase 3 CLEAR Trial
Presented By: Toni Choueiri, MD, FASCO
|
|
|
|
|
Biomarker Analysis of the Phase 3 KEYNOTE-426 Study of Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma
Presented By: Brian I. Rini, MD, FASCO
|
|
|
|
|
Circulating Kidney Injury Molecule-1 Biomarker Analysis in IMmotion010: A Randomized Phase 3 Study of Adjuvant Atezolizumab vs Placebo in Patients with RCC at Increased Risk of Recurrence After Resection
Presented By: Laurence Albiges, MD, Ph.D.
|
|
|
|
|
Avelumab + Axitinib vs Sunitinib in Patients with Advanced Renal Cell Carcinoma: Final Overall Survival Analysis from the JAVELIN Renal 101 Phase 3 Trial
Presented By: Robert J. Motzer, MD
|
|
|
|
|
Blood-Based Markers of Differential Efficacy of Bipolar Androgen Therapy and Enzalutamide in the Randomized TRANSFORMER Trial
Presented By: Samuel Denmeade, MD
|
|
|
|
|
What Is Variant Histology Urothelial Cancer and What Are the Available Treatment Options?
Presented By: Jean Hoffman-Censits, MD
|
|
|
|
|
| Comparing Patient Profiles and Treatment Outcomes with Radium-223 (223Ra) in Real-World Settings: Academic vs. Community Practice in the US—Insights from the REASSURE Study ePoster: E17040; Published J Clin Oncol 42, 2024, Suppl 16
|
|
|
|
|
